SCHEMBL3672928

SCHEMBL3672928

NC(=O)c1ccccc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
RECQL P46063 1/20 0.50
BCAT2 O15382 1/20 0.50
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
GALR3 O60755 1/20 0.47
LMNA P02545 1/20 0.47
NR2F2 P24468 1/20 0.47
DPP4 P27487 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238940 0.86 KDM4E (0.52) KDM4ERECQLBCAT2ALDH1A1SMN1; SMN2
SCHEMBL30863835 0.86 KDM4E (0.52) KDM4ERECQLBCAT2ALDH1A1SMN1; SMN2
SCHEMBL5110958 0.85 KDM4E (0.54) KDM4ERECQLBCAT2ALDH1A1SMN1; SMN2
SCHEMBL442223 0.84 ALDH1A1 (0.58) RECQLALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL29940950 0.83 BCAT2 (0.59) KDM4EBCAT2ALDH1A1SMN1; SMN2MAPT
SCHEMBL1203519 0.83 BCAT2 (0.59) KDM4EBCAT2ALDH1A1SMN1; SMN2MAPT
SCHEMBL5195579 0.81 DPP4 (0.47) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL2394244 0.79 CSNK2A2 (0.47) ALDH1A1SMN1; SMN2HTTGALR3LMNA
SCHEMBL24043882 0.79 CES2 (0.53) RECQLALDH1A1SMN1; SMN2HTTNPC1
SCHEMBL16871335 0.79 SLC6A3 (0.65) ALDH1A1HTTMAPTLMNACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090011935-A1 Method of Inducing Tolerance of Plants Against Bacterioses BASF SE (DE) 2009-01-08 US claimed
EP-1996018-A2 METHOD OF INDUCING TOLERANCE OF PLANTS AGAINST BACTERIOSES BASF SE (DE) 2008-12-03 EP claimed
WO-2007104658-A2 METHOD OF INDUCING TOLERANCE OF PLANTS AGAINST BACTERIOSES BASF SE (DE) 2007-09-20 WO claimed
EP-2392662-A2 Plant produtivity enhancement by combining chemical agents with transgenic modifications BASF SE (DE) 2011-12-07 EP disclosed
US-20100093715-A1 Plant productivity enhancement by combining chemical agents with transgenic modifications BASF SE (DE) 2010-04-15 US disclosed
WO-2009124920-A2 EMULSIFIABLE CONCENTRATE BASF SE (DE) 2009-10-15 WO disclosed
EP-2076602-A2 PLANT PRODUTIVITY ENHANCEMENT BY COMBINING CHEMICAL AGENTS WITH TRANSGENIC MODIFICATIONS BASF SE (DE) 2009-07-08 EP disclosed
US-20090011935-A1 Method of Inducing Tolerance of Plants Against Bacterioses BASF SE (DE) 2009-01-08 US disclosed
EP-1996018-A2 METHOD OF INDUCING TOLERANCE OF PLANTS AGAINST BACTERIOSES BASF SE (DE) 2008-12-03 EP disclosed
WO-2008129060-A2 PLANT PRODUTIVITY ENHANCEMENT BY COMBINING CHEMICAL AGENTS WITH TRANSGENIC MODIFICATIONS BASF SE (DE) 2008-10-30 WO disclosed
WO-2007104658-A2 METHOD OF INDUCING TOLERANCE OF PLANTS AGAINST BACTERIOSES BASF SE (DE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090011935-A1 Method of Inducing Tolerance of Plants Against Bacterioses BROX, CAT, SLC11A2 KDM4E 4657/4885RECQL 2085/4885BCAT2 142/4885
US-20100093715-A1 Plant productivity enhancement by combining chemical agents with transgenic modifications CBR3, MYB, HACL2 KDM4E 773/4885RECQL 4789/4885BCAT2 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.